Skip to main content

Table 1 Baseline clinical characteristics of the 821 patients with locally advanced nasopharynx of head and neck cancer

From: Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics

Characteristics

No. of patients (%)

Age, years

 <45

477 (58.1)

 ≥45

344 (41.9)

Sex

 Male

617 (75.2)

 Female

204 (24.8)

Histology, WHO typea

 II

14 (1.7)

 III

807 (98.3)

Smoking

 No

514 (62.6)

 Yes

307 (37.4)

Alcohol

 No

695 (84.7)

 Yes

126 (15.3)

Clinical stageb

 III

350 (42.6)

 IV

471 (57.4)

T stageb

 T1

48 (5.8)

 T2

71 (8.6)

 T3

388 (47.3)

 T4

314 (38.2)

N stageb

 N0

36 (4.4)

 N1

311 (37.9)

 N2

261 (31.8)

N3

213 (25.9)

NAC regimens

 TPF

501 (61.0)

 TP

194 (23.6)

 GP

54 (6.6)

 PF

61 (7.4)

 Othersc

11 (1.3)

NAC cycles

 2 cycles

393 (47.9)

 3 cycles

392 (47.7)

 4 cycles

36 (4.4)

  1. Abbreviations: GP Gemcitabine and cisplatin, N Node, NAC Neoadjuvant chemotherapy, PF Cisplatin and 5-fluorouracil, T Tumor, TP Docetaxel and cisplatin, TPF Docetaxel, cisplatin, and 5-fluorouracil, WHO World Health Organization
  2. aWHO Type II refers to the differentiated non-keratinizing carcinoma; WHO Type III refers to the undifferentiated non-keratinizing carcinoma
  3. bAccording to the 8th edition of the AJCC/UICC Staging System
  4. cOthers included patients with alteration of NAC regimens, for example switch from TPF to GP due to adverse events